NCCN and Evidence Blocks

NCCN and Evidence Blocks

NCCN2017

2 years
788 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Clifford Goodman, PhD of Lewin Group gives an overview of the National Comprehensive Cancer Network's (NCCN) guidelines program and the addition of the evidence blocks. He states that the evidence blocks have an element of affordability, which provides an opportunity for oncologists and other health care professionals to talk with patients about costs. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.
Up Next Autoplay
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Category: Non-Hodgkin Lymphoma
2 Views
ash 1 hour
REGN5458 @RutgersCancer #ASH #ASH19
REGN5458 @RutgersCancer #ASH #ASH19
Category: Multiple Myeloma
0 Views
ash 2 hours
Phase 3 ICARIA-MM trial of isatuximab #ASH19 #ASH @sanofi
Phase 3 ICARIA-MM trial of isatuximab #ASH19 #ASH @sanofi
Category: Multiple Myeloma
0 Views
ash 10 hours
CARTITUDE-1: How is This Different from Others? @MountSinaiNYC @DMadduri #ASH19 #ASH
CARTITUDE-1: How is This Different from Others? @MountSinaiNYC @DMadduri #ASH19 #ASH
Category: Multiple Myeloma
2 Views
ash 10 hours
CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528 @MountSinaiNYC @DMadduri
CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528 @MountSinaiNYC @DMadduri
Category: Multiple Myeloma
2 Views
ash 10 hours
CAR-T Cell Imaging Markers: How This Affects Clinicians @PennMedicine
CAR-T Cell Imaging Markers: How This Affects Clinicians @PennMedicine
Category: Immunotherapy
0 Views
Cancer-News 11 hours
How Sensitive is the Technology? @PennMedicine @sellmyerlab
How Sensitive is the Technology? @PennMedicine @sellmyerlab
Category: Immunotherapy
0 Views
Cancer-News 11 hours
CAR-T Cells With Imaging Markers @PennMedicine sellmyerlab @sellmyerlab
CAR-T Cells With Imaging Markers @PennMedicine sellmyerlab @sellmyerlab
Category: Immunotherapy
0 Views
Cancer-News 11 hours
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Category: Chronic Myelogenous Leukemia
4 Views
iCMLf 1 day
Perspectives on the Future of CML
Perspectives on the Future of CML
Category: Chronic Myelogenous Leukemia
2 Views
iCMLf 1 day